Opinion|Videos|September 19, 2024
Approved and Investigational Agents for Myelofibrosis
Author(s)David M. Swoboda, MD, Andrew T. Kuykendall, MD
Panelists discuss how Janus kinase (JAK) inhibitors, including ruxolitinib, fedratinib, pacritinib, and momelotinib, as well as investigational agents like pelabresib and navitoclax, target the dysregulated JAK-STAT pathway to manage symptoms and potentially modify disease progression in myelofibrosis.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Advertisement
Advertisement
Trending on CancerNetwork
1
Clinical Applications and the Future of Remote Endovascular Procedures
2
Building a Low-Dose Radiation Therapy Program for Benign Disease
3
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
4
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
5